Updated time: 2024-09-06 09:34:44
The present invention relates to the use of at least one anti-SCUBE2 monoclonal antibody, or fragments thereof, having binding specificity for both SCUBE2 expressed on human vascular endothelial cells and on murine endothelial cells. Anti-angiogenic therapy in mammals can be effected by administering to the mammalian host a therapeutically effective amount of an anti-SCUBE2 monoclonal antibody, or fragments thereof, which is conjugated to at least one angiogenesis inhibitor or antitumor agent. The composition is useful for treating tumors and angiogenesis-associated diseases such as, but not limited to, neovascular eye disorders.
Vascular endothelial growth factor (VEGF) plays a crucial role in angiogenesis. Because of its importance in angiogenesis, several medications have been developed to inhibit VEGF signaling and reduce blood vessel formation in angiogenesis-dependent diseases. Although these medications have proven to be effective for these diseases, they have been shown to cause side effects such as hypertension, artery clots, complications in wound healing, and gastrointestinal perforation. Compared with anti-VEGF therapy, SCUBE2 might be a safer and more effective antiangiogenic target in vivo for the following reasons.
- SCUBE2 is highly expressed by growing but not quiescent endothelial cells in culture. In addition, in vivo vascular phenotypes were not observed in Scube2-knockout mouse strains. These results suggest that targeting SCUBE2 therapies inhibit pathological neovascularization while having little or no effect on normal mature tissue vasculature.
- Endothelial cell (EC)-surface SCUBE2 is a vascular endothelial growth factor receptor 2 (VEGFR2) co-receptor essential for pathological tumor angiogenesis, and anti-SCUBE2 mAb acting as an internalization inducer. Our results suggest a new antiangiogenic strategy, which is to reduce local VEGF signaling by loss of endothelial SCUBE2. This new approach might be beneficial for patients with tumors that are resistant to anti-VEGF therapies.
- SCUBE2 was upregulated by hypoxia-inducible factor (HIF-1α) in response to hypoxic conditions. Based on its enhanced expression pattern in the tumor vasculature, we suggested the possible involvement in tumorigenesis, and other angiogenesis-dependent diseases, such age related macular degeneration, diabetic retinopathy, glaucoma, psoriasis, arthritis, and atherosclerosis.
12A-1050325
US 11066466 B2、TW I729393、JP 特許6938536、TW 786619、CN ZL 2017 8 0023573.8、、IN 470283、US 11,866,489 B2、TW I852158
- Inhibiting of tumor angiogenesis
- To prevent or reduce the neovascular eye disorders (eg., age related macular degeneration, diabetic retinopathy, and glaucoma……)
- SCUBE2 inhibition has beneficial effects on the other angiogenesis-dependent diseases (eg., psoriasis, arthritis, and atherosclerosis……)
Ruey-Bing Yang, Yuh-Charn Lin
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Request for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office

Inhibition of SCUBE2, a novel VEGFR2 co-receptor, suppresses tumor angiogenesis